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SELECTION OF THE MONTH 
Title of the Month: Big Title: Fructose increases risk of NAFLD in children 
 
Small title:  
Intrahepatic innate immunity in chronic HBV infection 
A comprehensive view on NS5A resistance  
Abnormal IFN signaling in cirrhosis PBMCs 
 
HEPATOCYTE POLARITY 
Role of VPS33B 
Hepatocyte polarization is crucial for normal cell function. Several cholestatic liver 
diseases with defects of hepatocyte polarity have been identified, but little is known 
about the molecular mechanisms explaining these defects. The attention of Hanley et 
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al. was drawn on a protein called “vacuolar protein sorting-associated protein 33B” 
(encoded by VSP33B) because a syndrome called “arthrogryposis, renal dysfunction 
and cholestasis” is most often caused by VPS33B mutations. Therefore, they 
investigated mice that were selectively deleted for Vsp33b in the liver. Their results 
indicate that Vsp33b in mice has a key role in establishing structural and 
functional aspects of hepatocyte polarity suggesting that VSP33B could be a 
target for gene replacement therapy in humans. 
 
LIVER SINUSOIDAL ENDOTHELIAL CELLS (LSECS) 
LSECS function as immunological platforms  
LSECs play a crucial role in liver physiology and pathophysiology. A function which is 
not well known by hepatologists is antigen presentation. In this issue of the Journal, 
Wittlich et al. present a scenario involving two categories of signals that modulate the 
production of the cytotoxic granzyme B by CD8 T cells. The primary signal is the 
activation CD8 T cells via engagement of T cell receptor by antigen presented by 
LESCs. In primed CD8 T cells additional interleukin (IL)-6 trans-signaling increases 
the expression of granzyme B, which depends on the stimulation of the IL-2-receptor 
by IL-2 secreted from Th1 cells. Accordingly, in this scenario IL-6 trans-signaling 
plays an important role in CD8 T cell activation and deserves some comment. The fully 
competent IL-6 receptor is composed of a type 1 cytokine α-receptor subunit (IL-6R, 
also known as CD126; encoded by IL6R), which binds IL-6, and a signal-transducing 
β-receptor subunit (gp130; also known as CD130; encoded by IL6ST). The expression 
of gp130 is ubiquitous on cells of the immune system and those not of the immune 
system. In contrast, IL-6R expression is restricted largely to hepatocytes, leukocytes 
and megakaryocytes. ‘Classical’ IL-6 receptor signaling denotes activities mediated via 
the membrane-bound IL-6R subunit and is relevant only to cells that express both 
receptor subunits. IL-6 “trans-signaling” refers to a process in which a soluble 
form of IL-6R binds secreted IL-6 to form a complex that binds any cell that 
expresses only gp130 which hence acquires IL-6 responsiveness. 
 
HEPATOCELLULAR CARCINOMA (HCC) 
Mutated ARID2, tumor suppressive microRNAs, modified RECIST 
SWI/SNF family complexes. are large chromatin-remodeling machines that move or 
eject nucleosomes, providing proper nucleosome positioning and density at genes and 
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other loci. SWI/SNF-family complexes are involved in a broad variety of functions 
including transcription, DNA repair, cell cycle and differentiation, and tumor 
suppression, among others. The AT-rich interaction domain 2 gene (ARID2) encodes 
a DNA-binding protein known as BAF200 which is one of the subunit composing 
SWI/SNF complexes. Although inactivating ARID2 mutations are known to be 
associated with HCC, the impact of ARID2 deletion was poorly understood until 
recently. To address this question, Oba et al. deleted ARID2 using CRISPR/Cas9 
system in HCC cell lines. They show that ARID2 knockout contributes to disruption of 
nucleotide excision repair process through inhibiting the recruitment of a protein called 
“DNA repair protein complementing XP-G cells” (encoded by ERCC5 also known as 
XPG, XPGC). ARID2 deletion resulted in increased susceptibility to carcinogens and 
potential hyper mutation. These findings have far-reaching implications for 
therapeutic targets in HCC with ARID2 mutations. 
MicroRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-
transcriptional regulation of gene expression in multicellular organisms by affecting 
both the stability and translation of mRNAs. MiRNAs regulate the expression of a broad 
variety of genes and therefore impact multiple functions. MiR-499a has been shown to 
have anti-cancer effects in HCC lines. Here, Sandboth et al. report their investigations 
on three members of the miR-499 family (miR-499a, miR-499b, and miR-499c). They 
show distinct tumor suppressive effects and target specificities of miR-449a, 
miR-449b, and miR-449c. Moreover, their results suggest that miR-449a and miR-
449b could be considered for miRNA replacement therapy to prevent HCC progression 
and metastasis.  
The Response Evaluation Criteria in Solid Tumors (RECIST) have been challenged in 
HCC due to the nature of effective treatments. This is why these criteria have been 
changed giving rise to modified RECIST (mRECIST). Lencioni et al. investigated 
whether objective response by mRECIST accurately predict overall survival in patients 
with advanced HCC treated by systemic therapies. For this they performed an 
individual patient data analysis of BRISK-PS, a phase III trial comparing brivanib and 
placebo in the second line setting. They show that objective response by mRECIST 
in advanced HCC predicts overall survival and thus can be considered as a 
candidate surrogate for prognostic end point. 
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FATTY LIVER DISEASE 
Fructose consumption and hyperuricemia in young population, CAP technology 
and inflammasome blockade in NAFLD  
Excessive fructose intake is known to increase serum uric acid concentrations. In an 
important study by Mosca et al. a large cohort of children and adolescents with proven 
NAFLD (37% with NASH) were studied. Hyperuricemia was present in 47% of patients 
with NASH compared with 29% of Not-NASH patients. Importantly, both uric acid 
concentration and fructose consumption were independently associated with 
NASH, after adjustment for multiple confounders. Importantly, fructose consumption 
was the only factor independently associated with serum uric acid 
concentration. This study suggests that excessive fructose consumption could lead 
to hyperuricemia and contribute to NASH development in young populations. Public 
health policies aimed at preventing excessive fructose-containing beverages among 
children are warranted. In another study in this issue, Karlas et al. study the 
usefulness of ultrasound-based controlled attenuation parameter (CAP) in 
detecting steatosis, an increasing liver condition worldwide. In an individual patient 
data meta-analysis, the authors gathered data from 19 studies comprising more than 
3.000 patients. Seventy percent of patients have viral hepatitis and 20% NAFLD. CAP 
values in dB/m were influenced by several covariates with an estimated shift for 
NAFLD, diabetics and per BMI unit. Optimal cutoffs were 248 and 268 for those above 
S0 and S1. The authors conclude that CAP provides a standardized non-invasive 
measure of hepatic steatosis and that the etiology, diabetes, and BMI deserve 
consideration when interpreting CAP. This study should be confirmed in populations 
with alcoholic liver disease.  
Finally, in this issue of the Journal a new potential targeted therapy for NAFLD was 
proposed. NOD-like receptor protein 3 (NLRP3) inflammasome activation occurs in 
both alcoholic and non-alcoholic fatty liver. Mridha et al. used the first small molecule 
NLRP3 inhibitor, MCC950, in two murine models of steatohepatitis. MCC950 
treatment lowered serum transaminases, reduced the severity of liver 
inflammation and fibrosis and reduced caspase activation. In vitro, MCC950 
attenuated the effect of cholesterol crystals on Kupffer cells and macrophages to 
release inflammatory mediators. These preclinical research strongly indicates that 
targeting NLRP3 is a promising therapeutic option in patients with NAFLD and 
deserves clinical attention. 
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HEPATITIS B VIRUS (HBV) INFECTION 
Intrahepatic innate immunity in chronic HBV infection, 
Most of our knowledge on HBV specific host immune responses was obtained from 
studies with peripheral blood rather than by studying the liver. The study by Lebossé 
et al. is the first that examines in detail the intrahepatic innate immune gene expression 
in chronic HBV compared to healthy livers. Their results indicate that chronic HBV 
infection has a profound suppressive effect on host innate immune responses, 
which was more pronounced in the presence of high levels of hepatitis B virus 
surface antigen (HBsAg). These data provide novel insight into the complex virus-
host interactions and the mechanisms of HBV persistence in the liver, and suggest that 
novel HBsAg targeting approaches may also restore immune responsiveness (see 
also the Editorial by Vanwolleghem and Boonstra). 
 
HEPATITIS C VIRUS (HCV) INFECTION 
A comprehensive view on NS5A resistance, persistence of immunosuppressive 
Tregs after SVR, autocrine regulation of HCV replication 
The extent by which the presence of NS5A resistance-associated substitutions (RASs) 
can affect the efficacy of NS5A inhibitor-containing antiviral regimens in previously 
untreated as well as treatment-experienced HCV-infected patients is still a matter of 
debate. Zeuzem et al. reviewed results from 35 clinical trials where patients with HCV 
type 1 infection received treatments that included ledipasvir plus sofosbuvir. They 
found that by using a 15% cut-off, ledipasvir-specific NS5A RASs were present in 8-
16% prior to treatment, and had a negative impact on treatment outcome in certain 
subsets of patients, in particular treatment-experienced patients with HCV subtype 1a. 
This comprehensive large scale analysis teaches us the importance of a 
balanced approach when considering RAS testing before NS5A-containing 
regimens but also that large numbers are needed to uncover small differences.  
During chronic hepatitis C, effector T cells become progressively exhausted and exhibit 
reduced antiviral activity, while CD4+ regulatory T cells (Tregs) gradually expand and 
accumulate in the liver and being linked to fibrogenesis and liver cancer development. 
Langhans et al. studied the long-term evolution of Tregs in HCV-infected patients 
treated with either interferon (IFN)-containing or IFN-free direct acting antiviral (DAA) 
treatment. Although IFN-based DAA therapy induced transient expansion of activated 
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Foxp3+CD25+CD4+ T cells, neither IFN-based nor IFN-free DAA regimens normalized 
frequencies and activation status of Tregs one year after viral elimination. The 
persistence of immunosuppressive Tregs may thus contribute to complications 
of liver disease even long-term after HCV elimination, following the concept that 
cure of the infection does not necessarily means cure of the disease. 
The protein called “ectonucleotide pyrophosphatase/phosphodiesterase family 
member 2” (known as autotaxin; encoded by ENPP2, alias ATX), hydrolyzes 
lysophosphatidylcholine (LPC) to the growth factor lysophosphatidic acid (LPA). The 
autotaxin-LPA signaling axis plays an important role in both normal physiology and 
disease pathogenesis, and recently has been linked to pruritus in chronic cholestatic 
liver diseases. The current elegant study by Farquhar et al. uncover a role for the 
autotaxin-LPA signaling axis to positively regulate HCV replication by activating PI3K 
and stabilizing HIF-1α, hereby providing evidence for an autocrine LPA feedback loop 
to promote viral replication. The data support a model where HCV infection increases 
hepatocellular autotaxin expression that promotes viral replication and 
establishes a paracrine LPA-signaling environment leading to fibrosis and HCC 
pathogenesis. 
 
CIRRHOSIS 
IFN signaling in PBMCs of alcoholic cirrhosis patients  
Patients with decompensated alcoholic cirrhosis show evidence of widespread 
disturbances in immune function ranging from inflammatory phenotype to that of a 
reparative anti-inflammatory phenotype. Type I interferons are a family of cytokines 
that play a crucial role in the immune response to viral pathogens that result in 
transcription of interferon stimulated genes (ISG). Weiss et al. studied the peripheral 
blood mononuclear cells from a large number of patients with alcoholic cirrhosis 
and show for the first time that both constitutive and stimulated ISG expression 
was abnormal and, the higher the baseline ISG expression, the greater was the 
risk of death. The data provide the basis of a novel biomarker to identify those patients 
at risk and also a potential therapeutic target. 
 
